Abatacept: Phase III data

In the double-blind, placebo-controlled Phase III AIM trial in 547 patients, 73.1% of patients given 10 mg/kg abatacept IV treatment for 12 months, achieved an ACR 20 response vs. 39.7% on placebo (p<...